Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Next Previous
Trial Profile

A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Status: Suspended
Phase of Trial: Phase II/III

Latest Information Update: 06 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Cisplatin (Primary) ; Doxorubicin (Primary) ; Methotrexate (Primary)
  • Indications Bone metastases; Cancer metastases; Osteosarcoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 07 Sep 2023 Status changed from recruiting to suspended due to scheduled Interim Monitoring.
  • 11 Aug 2023 Status changed from suspended to recruiting.
  • 13 Jul 2023 Status changed from recruiting to suspended (Scheduled Interim Monitoring).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top